“Years later, this breakthrough would be the key to delivering Moderna’s mRNA vaccine into the targeted cells that would trigger an immune response in the body.” – Northwestern complaint ...

Moderna's Stéphane Bancel is stepping down from his role as chief commercial officer, a significant shift for the company as it approaches the rollout of several new vaccines. Source: Pixabay.

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Northwestern University filed a patent infringement ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based ...

Moderna surveyed 3,000 adults in the U.K. to gauge awareness of vaccine eligibility criteria. The survey found 32% of people with underlying health conditions don’t know they are eligible for ...

GSK claims Moderna used its patented mRNA vaccine platform without a license, reaping billions from vaccine sales. The Mandl team at GSK developed a pioneering mRNA platform that has set the ...

TORONTO - Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — but it won’t be available until next year, the company ...

Oct 16 (Reuters) - Moderna (MRNA.O), opens new tab was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the ...

Covid vaccine sales totaled $1.8 billion for the third quarter. That blew past analysts’ estimates of $1.2 billion, and was slightly higher than a year earlier. Moderna's stock rose nearly 1.5% ...

(Reuters) - Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new ...